Search

Search Results

• THROMBOCYTOPENIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES - STILL AN UNSOLVED PROBLEM

  May Basood, Howard S. Oster, Moshe Mittelman

  e2018046

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.046

  3222

  PDF: 1413

  HTML: 566

• INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY

  Giuseppe Leone, Livio Pagano

  e2018039

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.039

  4302

  PDF: 1473

  HTML: 626

• DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES: ANALOGIES AND DIFFERENCES DE NOVO AND THERAPY-RELATED MYELODYSPLASTIC SYNDROMES

  Prof. Giuseppe Leone, Emiliano Fabiani, Maria Teresa Voso

  e2022030

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.030

  1426

  HTML: 485

  PDF: 846

• IMPORTANCE OF CLASSICAL MORPHOLOGY IN THE DIAGNOSIS OF MYELODYSPLASTIC SYNDROME

  Rosangela Invernizzi, Federica Quaglia, Matteo Giovanni Della Porta

  e2015035

  2015-04-26

  https://doi.org/10.4084/mjhid.2015.035

  3423

  PDF: 2296

  HTML: 23375

  Untitled: 214

  Untitled: 228

  Untitled: 242

• DIAGNOSTIC UTILITY OF FLOW CYTOMETRY IN MYELODYSPLASTIC SYNDROMES.

  Matteo Della Porta, Cristina Picone

  e2017017

  2017-02-15

  https://doi.org/10.4084/mjhid.2017.017

  4873

  PDF: 1857

  HTML: 2171

• A POPULATION-BASED STUDY ON MYELODYSPLASTIC SYNDROMES IN THE LAZIO REGION (ITALY), MEDICAL MISCODING AND 11-YEAR MORTALITY FOLLOW-UP: THE GRUPPO ROMANO-LAZIALE MIELODISPLASIE EXPERIENCE OF RETROSPECTIVE MULTICENTRIC REGISTRY

  Flavia Mayer, Laura Faglioni, Nera Agabiti, Susanna Fenu, Francesco Buccisano, Roberto Latagliata, Roberto Ricci, Maria Antonietta Aloe Spiriti, Caterina Tatarelli, Massimo Breccia, Giuseppe Cimino, Luana Fianchi, Svitlana Gumenyuk, Stefano Mancini, Luca Maurillo, Carolina Nobile, Pasquale Niscola, Anna Lina Piccioni, Agostino Tafuri, Giulio Trapè, Alessandro Andriani, Paolo De Fabritis, Maria Teresa Voso, Marina Davoli, Gina Zini

  e2017046

  2017-07-01

  https://doi.org/10.4084/mjhid.2017.046

  2746

  PDF: 1025

  HTML: 1119

• NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES

  Francesco D'Alò, Mariangela Greco, Marianna Criscuolo, Maria Teresa Voso

  e2010021

  2010-08-11

  https://doi.org/10.4084/mjhid.2010.021

  2016

  PDF: 915

  HTML: 704

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2213

  PDF: 1740

  HTML: 386

• MYELODYSPLASTIC SYNDROMES AND IRON CHELATION THERAPY

  Emanuele Angelucci, Silvana Anna Maria Urru, Federica Pilo, Alberto Piperno

  e2017021

  2017-03-01

  https://doi.org/10.4084/mjhid.2017.021

  3461

  PDF: 1320

  HTML: 1923

  Fig.1: 223

  Fig. 2: 221

• RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES

  Julie Schanz, Friederike Braulke, Detlef Haase

  e2015034

  2015-04-23

  https://doi.org/10.4084/mjhid.2015.034

  3858

  PDF: 1699

  HTML: 11658

  Figures Haase: 219

• REFRACTORY THROMBOCYTOPENIA AND NEUTROPENIA: A DIAGNOSTIC CHALLENGE

  Emmanuel Gyan, François Dreyfus, Pierre Fenaux

  e2015018

  2015-02-13

  https://doi.org/10.4084/mjhid.2015.018

  12578

  PDF: 1699

  HTML: 4233

  Cover letter: 209

  Figure 1: 216

• ROLE AND TIMING OF HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME

  Teresa L Field, Claudio Anasetti

  e2010019

  2010-07-19

  https://doi.org/10.4084/mjhid.2010.019

  1386

  PDF: 686

  HTML: 1190

• HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS

  Mazyar Shadman, Joachim Deeg

  e2014056

  2014-09-01

  https://doi.org/10.4084/mjhid.2014.056

  2084

  PDF: 784

  HTML: 3119

• CLINICO-PATHOLOGICAL SPECTRUM AND NOVEL KARYOTYPIC FINDINGS IN MYELODYSPLASTIC SYNDROME: EXPERIENCE OF TERTIARY CARE CENTRE IN INDIA.

  Ruchi Gupta, Khaliqur Rahman, Manish Kumar Singh, Surabhi Kumari, Geeta yadav, Soniya Nityanand

  e2017048

  2017-08-16

  https://doi.org/10.4084/mjhid.2017.048

  2046

  PDF: 826

  HTML: 951

  Untitled: 217

• TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS

  Luca Maurillo, Francesco Buccisano, Maria Ilaria Del Principe, Chiara Sarlo, Luigi Di Caprio, Concetta Ditto, Federica Giannotti, Daniela Nasso, Eleonora Ceresoli, Massimiliano Postorino, Marco Refrigeri, Sergio Amadori, Adriano Venditti

  e2013032

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.032

  2865

  PDF: 1034

  HTML: 5531

• RECENT ADVANCES IN THE 5Q- SYNDROME

  Andrea Pellagatti, Jacqueline Boultwood

  e2015037

  2015-05-20

  https://doi.org/10.4084/mjhid.2015.037

  2847

  PDF: 1850

  HTML: 3691

  Pellagatti Fig 1: 227

  Pellagatti Fig. 2: 219

• ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN THERAPY-RELATED MYELOID NEOPLASMS (t-MN) OF THE ADULT: MONOCENTRIC OBSERVATIONAL STUDY AND REVIEW OF THE LITERATURE.

  Elisabetta Metafuni, Patrizia Chiusolo, Luca Laurenti, Federica Sorà, Sabrina Giammarco, Andrea Bacigalupo, Giuseppe Leone, Simona Sica

  e2018005

  2018-01-01

  https://doi.org/10.4084/mjhid.2018.005

  4235

  PDF: 1106

  HTML: 1371

• ASSOCIATION BETWEEN LEUKEMIC EVOLUTION AND UNCOMMON CHROMOSOMAL ALTERATIONS IN PEDIATRIC MYELODYSPLASTIC SYNDROME

  Viviane Lamim Lovatel, Beatriz Ferreira da Silva , Eliane Ferreira Rodrigues , Maria Luiza Rocha da Rosa Borges , Rita de Cássia Barbosa Tavares, Ana Paula Silva Bueno, Elaine Sobral da Costa, Terezinha de Jesus Marques , Teresa de Souza Fernandez

  e2024003

  2024-01-01

  https://doi.org/10.4084/MJHID.2024.003

  1210

  PDF: 1399

  HTML: 138

• A case of atypical prolonged hematologic toxicity with azacitidine in Chronic Myelomonocytic Leukemia (CMML), review of literature and a proposal of management

  Elena Elli, Caterina Cecchetti, Angelo Belotti, Lorenza Borin, Enrico Maria Pogliani

  e2012017

  2012-03-13

  https://doi.org/10.4084/mjhid.2012.017

  1257

  PDF: 664

  HTML: 764

• miR-155-5p PROMOTES CD34+ APOPTOSIS AND INHIBITS BONE MARROW HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES BY RAC1/CREB/MIR-15B AXIS

  Meiwan Cao, BaoLing Peng, WanFu Xu, PeiYu Chen, Huan Chen, LiPing Ye, Jing Xie, HongLi Wang, Lu Ren, LiYa Xiong, JingNan Zhu, XiangYe Xu, LanLan Geng, SiTang Gong

  e2023040

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.040

  769

  PDF: 892

  PDF Supp. Files: 81

  HTML: 196

• BONE MARROW MICROENVIRONMENT INVOLVEMENT IN T-MN: FOCUS ON MESENCHYMAL STEM CELLS MESENCHYMAL STEM CELL IN T-MN

  Maria Teresa Voso, Giulia Falconi, Dr. Fabiani

  e2023055

  2023-08-29

  https://doi.org/10.4084/MJHID.2023.055

  1859

  PDF: 1014

  HTML: 148

• PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL P53 EXPRESSION IN BONE MARROW BIOPSY IN HIGHER RISK MDS: A PILOT STUDY

  Alfredo Molteni, Emanuele Ravano, Marta Riva, Michele Nichelatti, Laura Bandiera, Lara Crucitti, Mauro Truini, Roberto Cairoli

  e2019015

  2019-02-26

  https://doi.org/10.4084/mjhid.2019.015

  1895

  PDF: 1003

  HTML: 337

• TREATMENT OF LOW-BLAST COUNT AML USING HYPOMETHYLATING AGENTS

  Eleonora De Bellis, Luana Fianchi, Francesco Buccisano, Marianna Criscuolo, Luca Maurillo, Laura Cicconi, Mattia Brescini, Maria Ilaria Del Principe, Ambra Di Veroli, Adriano Venditti, Francesco Lo-Coco, Maria Teresa Voso

  e2017045

  2017-07-01

  https://doi.org/10.4084/mjhid.2017.045

  4418

  PDF: 1784

  HTML: 1112

• CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2022069

  2022-08-27

  https://doi.org/10.4084/MJHID.2022.069

  3151

  PDF: 928

  HTML: 2085

• Anemia in the elderly: not always what it seems.

  Marco Cerrano, Elena Crisà, Valentina Giai, Mario Boccadoro, Dario Ferrero

  e2016017

  2016-02-25

  https://doi.org/10.4084/mjhid.2016.017

  3349

  PDF: 1098

  HTML: 1788

  Figure 1: 192

  Figure 1 revised: 191

• PERPHERAL BLOOD CELL MITOCHONDRIAL DYSFUNCTION IN MYELODYSPLASTIC SYNDROMECAN BE IMPROVED BY A COMBINATION OF COENZYME Q10 AND CARNITINE Blood cell mitochondrial dysfunction in myelodysplastic syndrome

  Kalman Filanovsky, Michal Haran, Vita Mirkin, Andrei Braester, Olga Shevetz, Anfisa Stanevsky, Erica Sigler, Ekaterina Votinov, Yehudit Zalzman-Amir, Alain Berrebi, Atan Gross, Lev Shvidel

  e2020072

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.072

  1177

  PDF: 792

  HTML: 335

• GENETIC PREDISPOSITION TO HEMATOLOGIC MALIGNANCIES IN CHILDHOOD AND ADOLESCENCE

  Francesco Fabozzi, Angela Mastronuzzi

  e2023032

  2023-04-28

  https://doi.org/10.4084/MJHID.2023.032

  2034

  PDF: 530

  HTML: 594

• ASSESSMENT OF CONGENITAL NEUTROPENIA IN CHILDREN: COMMON CLINICAL SCENERIES AND CLUES FOR MANAGEMENT Assessment of congenital neutropenia in children

  Ilaria Lazzareschi, Elena Rossi, Antonietta Curatola, Giovanna Capozio, Luca Benacquista, Ludovica Iezzi, Donato Rigante

  e2022008

  2022-01-01

  https://doi.org/10.4084/MJHID.2022.008

  2370

  PDF: 1194

  HTML: 688

• DECREASED CD10 EXPRESSION IN THE BONE MARROW NEUTROPHILS OF HIV POSITIVE PATIENTS

  Annemarie Van de Vyver, Adele Visser

  e2010032

  2010-11-10

  https://doi.org/10.4084/mjhid.2010.032

  1339

  PDF: 888

  HTML: 1160

  Coverletter: 226

• PROGNOSIS AND THERAPY WHEN ACUTE PROMYELOCYTIC LEUKEMIA AND OTHER “GOOD RISK” ACUTE MYELOID LEUKEMIAS OCCUR AS A THERAPY-RELATED MYELOID NEOPLASM

  Richard A. Larson, Michelle Le Beau

  e2011032

  2011-07-08

  https://doi.org/10.4084/mjhid.2011.032

  2886

  PDF: 948

  HTML: 1883

• THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition

  Emiliano Fabiani, Dr. Falconi, Dr. Cristiano, Dr. Hajrullaj, Dr. Falconi, Prof. Leone, Prof. Voso

  e2023064

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.064

  1414

  PDF: 869

  HTML: 146

• THERAPEUTIC OPTIONS FOR PATIENTS WHO ARE NOT ELIGIBLE FOR INTENSIVE CHEMOTHERAPY

  Elihu Estey

  e2013050

  2013-07-12

  https://doi.org/10.4084/mjhid.2013.050

  2211

  PDF: 761

  HTML: 1638

• 5-Azacytidine in chronic myelomonocytic leukemia: case report and review of literature

  Mariangela Greco, Marianna Criscuolo, Luana Fianchi, Livio Pagano, Maria Teresa Voso

  e2011011

  2011-03-14

  https://doi.org/10.4084/mjhid.2011.011

  1648

  PDF: 775

  HTML: 1124

• Azacytidine failure revisited: an appraisal based on real life data from the MDS registry of the Hellenic Myelodysplastic Syndrome Study Group (HMDS). Azacytidine failure revisited

  IOANNIS KOTSIANIDIS

  e2019045

  2019-06-25

  https://doi.org/10.4084/mjhid.2019.045

  1119

  PDF: 878

  HTML: 255

• IRON CHELATION THERAPY WITH DEFERASIROX IN THE MANAGEMENT OF IRON OVERLOAD IN PRIMARY MYELOFIBROSIS

  Elena Maria Elli, Angelo Belotti, Andrea Aroldi, Matteo Parma, Pietro Pioltelli, Enrico Maria Pogliani

  e2014042

  2014-05-30

  https://doi.org/10.4084/mjhid.2014.042

  2179

  PDF: 1174

  HTML: 2014

• Seven-Year Course of Hypoplastic Myelodysplastic Syndrome Unmasked by Secondary and Neurosyphilis.

  Ali Turunç, Hüseyin Derya Dinçyürek, Birol Güvenç

  e2026026

  2026-02-28

  https://doi.org/10.4084/MJHID.2026.026

  524

  PDF: 361

  HTML: 201

• Routine inflammatory markers are elevated in myelodysplastic syndromes at presentation Inflammatory marker elevation in MDS

  Howard Oster, Ekaterina Sklyar, Noa Golsdshmidt, Moshe Mittelman

  e2023044

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.044

  910

  PDF: 686

  HTML: 237

• ANTIFUNGAL PROPHYLAXIS IN IMMUNOCOMPROMISED PATIENTS

  Lourdes Vazquez

  e2016040

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.040

  4372

  PDF: 1401

  HTML: 2064

• Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapy

  Antonella Vaccarino, Irene Dogliotti, Fabio Marletto, Andrea Demarchi, Mario Bazzan

  e2016050

  2016-10-20

  https://doi.org/10.4084/mjhid.2016.050

  2834

  PDF: 780

  HTML: 1287

  Blood Count trend before and during lenalidomide treatment: 184

  Light micrograph of bone marrow biopsy of a patient with PV and 5q deletion: 199

• THE IMPORTANCE OF TARGETED NEXT-GENERATION SEQUENCING USAGE IN CYTOGENETICALLY NORMAL MYELOID MALIGNANCIES Targeted next-generation sequencing usage in cytogenetically normal myeloid malignancies

  Emine Atli, Rasime Kalkan, Cisem Mail, Damla Eker, Ufuk Demirci, Selma Demir, Sinem Yalcintepe, Hakki Onur Kirkizlar, Engin Atli, Hakan Gurkan, Ahmet Muzaffer Demir

  e2021013

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.013

  1643

  PDF: 567

  HTML: 298

• Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

  Alhossain A. Khalafallah, Bernadene Fernandopulle, Terry Brain

  e2010012

  2010-05-31

  https://doi.org/10.4084/mjhid.2010.012

  1078

  PDF: 703

  HTML: 351

• Myeloid neoplasms with isolated isochromosome 17q: a yet to be defined entity

  Eleftheria Lamprianidou, Chryssoula Kordella, Menelaos Papoutselis, Zoi Bezyrgiannidou, Evangelia Nakou, Spyros Papamichos, Emmanouil Spanoudakis, Andreas Giannopoulos, Katerina Zoi, Ioannis Kotsianidis

  e2017066

  2017-11-01

  https://doi.org/10.4084/mjhid.2017.066

  2336

  PDF: 801

  HTML: 934

• ACTIVIN RECEPTOR LIGAND FOR THR TREATMENT OF BETA-THALASSEMIA: a SERENDIPITOUS DISCOVERY

  Irene Motta, Valentina Brancaleoni, Isabella Nava, Paola Delbini, Lorena Duca

  e2020075

  2020-10-27

  https://doi.org/10.4084/mjhid.2020.075

  1602

  PDF: 1438

  HTML: 529

• THERAPY-RELATED MYELOID NEOPLASMS IN PATIENTS TREATED FOR HODGKIN LYMPHOMA

  Dennis A Eichenauer, Andreas Engert

  e2011046

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.046

  2329

  PDF: 776

  HTML: 1213

• THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA

  Xenofon Papanikolaou, Bart Barlogie, Saad Usmani

  e2011047

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.047

  2517

  PDF: 802

  HTML: 1742

• Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in a Child with Myelodysplastic Neoplasm with Complex Karyotype and ETV6 Variant: Challenges in Treatment

  Elaiza Almeida Antônio de Kós , Viviane Lamim Lovatel , Rita de Cássia Barbosa Tavares , Gerson Moura Ferreira , Bernadete Evangelho Gomes, Ana Paula Silva Bueno, Elaine Sobral da Costa , Teresa de Souza Fernandez

  e2024040

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.040

  867

  PDF: 984

  HTML: 98

• AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA: AN EFFECTIVE AND MANAGEABLE APPROACH.

  Pasquale Niscola

  e2014020

  2014-02-16

  https://doi.org/10.4084/mjhid.2014.020

  1759

  PDF: 911

  HTML: 2788

• INCIDENCE OF ACUTE MYELOID LEUKEMIA AFTER BREAST CANCER

  Caterina Giovanna Valentini, Luana Fianchi, Maria Teresa Voso, Morena Caira, Giuseppe Leone, Livio Pagano

  e2011069

  2011-12-22

  https://doi.org/10.4084/mjhid.2011.069

  3338

  PDF: 967

  HTML: 2972

• IMPACT OF COVID-19 ON OUTCOMES OF PATIENTS WITH HEMATOLOGIC MALIGNANCIES: A MULTI-CENTER, RETROSPECTIVE STUDY COVID-19 and hematologic malignancy

  İbrahim Halil Açar, Sebnem Izmir Güner , Muzeyyen Aslaner Ak, Mesut Gocer, Erman Ozturk , Figen Atalay, Gulden Sincan , Aysun Senturk Yikilmaz, Omer Ekinci, Idris Ince, Emine Gulturk , Nazli Demir, Ali Dogan, Yildiz Ipek, Birol Guvenc

  e2022074

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.074

  1620

  PDF: 808

  HTML: 223

• MOLECULAR PATHOGENESIS OF SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA

  Melanie Joannides, Ashley N Mays, Anita R Mistry, Syed Khizer Hasan, Andreas Reiter, Joseph L Wiemels, Carolyn A Felix, Francesco Lo-Coco, Neil Osheroff, Ellen Solomon, David Grimwade

  e2011045

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.045

  2921

  PDF: 872

  HTML: 6538

  Untitled: 250

  Untitled: 203

  Untitled: 224

  Untitled: 231